This technical application poster, originally showcased at ISCT 2024, demonstrates OmniaBio’s expertise in process development and GMP manufacturing of potent lentiviral vectors (LVVs) through two case studies:
Case Study 1: Optimizing Transient Transfection for Preclinical CAR Construct
- 2X increase in vector titer achieved by optimizing CAR % in GMP compliant HEK293 suspension cell line.
- Successful scale-up was confirmed in stirred tank bioreactors (STR) with no loss in titer.
- Vector transduced T-cells at ≥70%
Case Study 2: Enhancing Lentiviral Vector Production Efficiency through Optimization and Cost Analysis of OmniaBio’s HEK293 Suspension Cell Line Platform
- Significantly increased yields through optimized additives and feed strategy
- Additional increase in LVV production by optimizing plasmid ratio.
- Platform process has demonstrated improved cost-effectiveness compared to a competitor
Download this poster to learn how we can help streamline your LVV program journey to market.
About OmniaBio
As a dedicated cell and gene therapy CDMO, OmniaBio's vision is to manufacture a disease-free future. Headquartered in Ontario, Canada, our core values of collaborative partnership converge with deep industry experience and innovation using the latest technologies to drive the future of cell and gene therapy manufacturing.
